IGF2 and hepatocellular carcinoma: In accordance with previous studies that reported IGF2 LOI incidence and IGF2-miR-483 amplification in ~15% of primary liver tumors20,24,27, we observed overexpression of IGF2 and miR-483-3p in 4 out of 18 tumors obtained from HCC patients (Supplementary Fig. 4E).